Could a headset tame inflammation in duchenne muscular dystrophy?

NCT ID NCT07543302

ENROLLING_BY_INVITATION Disease control Sponsor: taVNS AB Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests a device called Travagus One, which stimulates a nerve in the ear to reduce inflammation in boys with Duchenne muscular dystrophy (DMD). Twenty boys aged 5-17 will use the headset at home for 5 minutes twice a day for one week. Researchers will measure inflammatory markers in blood samples before and after treatment to see if the device is safe and can lower inflammation, potentially offering an alternative to high-dose steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
transcutaneous auricular vagus nerve stimulation (taVNS) device
What this could lead to
If it works, this could point toward a safer anti-inflammatory treatment for Duchenne muscular dystrophy, reducing the need for high-dose steroids with their severe side effects.
What could go wrong
This is a very early pilot study with only 20 participants and one week of treatment. The device may not reduce inflammation enough to make a real difference, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Astrid Lindgren Children´s Hospital

    Stockholm, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.